Ousia Pharma ApS: Financial statements 2024
CVR: 43055909
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Ousia Pharma ApS (CVR 43055909) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -3,655,869 and a net result of DKK -5,348,579 compared with DKK -3,746,803 the year before. Equity in the 2024 report amounted to DKK -10,086,877. The company had 6 employees in the financial year.
- Gross Profit
- DKK -3,655,869
- Profit/Loss
- DKK -5,348,579
- Equity
- DKK -10,086,877
- Total Assets
- DKK 5,089,817
- Employees
- 6
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -3.7 mio. | -5.3 mio. | -10.1 mio. | 6 |
| 2023 | - | -2.2 mio. | -3.7 mio. | -4.7 mio. | 5 |
| 2022 | - | -645 t. | -904 t. | -864 t. | 3 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Ousia Pharma ApS has published its annual report for 2023. Gross profit came to DKK -2,239,754, and the net result was DKK -3,746,803.
About Ousia Pharma ApS
Ousia Pharma ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2022. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Ouisa Pharma ApS. The management consists of Anders Bue Klein, Christoffer Clemmensen and Jonas Odgaard Petersen. The board consists of Gaurav Gupta (chair), Menelas Nicolas Pangalos, Otello Stampacchia and Ramesh Rajanikant Bhatt. The company is owned by JLSa2 Therapeutics, Inc.. The company has 8 employees (2026). In 2025, the company reported a gross profit of DKK -10,204,929 and a net result of DKK -12,777,761 compared with DKK -5,348,579 the year before. Equity in the 2025 report amounted to DKK 11,818,220.